David Neff
About
David Neff is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics.
According to data from OpenAlex, David Neff has authored 39 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Surgery, 16 papers in Endocrinology, Diabetes and Metabolism and 14 papers in Economics and Econometrics. Recurrent topics in David Neff's work include Lipoproteins and Cardiovascular Health (28 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (15 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). David Neff is often cited by papers focused on Lipoproteins and Cardiovascular Health (28 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (15 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). David Neff collaborates with scholars based in United States, Italy and United Kingdom. David Neff's co-authors include Joanne E. Tomassini, Alberico L. Catapano, Brian A. Ference, Jennifer G. Robinson, M. John Chapman, Robert D. Brook, Robert P. Giugliano, George Davey Smith, Sergio Fazio and Marc S. Sabatine and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.
In The Last Decade
David Neff
39 papers receiving 1.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| David Neff United States | 17 | 938 | 394 | 299 | 269 | 233 | 39 | 1.4k | ||
| Jong-Soon Park United States | 12 | 793 0.8× | 632 1.6× | 171 0.6× | 375 1.4× | 133 0.6× | 27 | 1.7k | ||
| Mary P. McGowan United States | 16 | 1.6k 1.7× | 714 1.8× | 415 1.4× | 506 1.9× | 461 2.0× | 46 | 2.1k | ||
| Antonio J. Vallejo‐Vaz Spain | 19 | 877 0.9× | 469 1.2× | 172 0.6× | 369 1.4× | 282 1.2× | 51 | 1.5k | ||
| Jonathan L. Isaacsohn United States | 22 | 1.5k 1.6× | 725 1.8× | 266 0.9× | 582 2.2× | 289 1.2× | 50 | 2.4k | ||
| Emil M. deGoma United States | 19 | 667 0.7× | 425 1.1× | 102 0.3× | 365 1.4× | 242 1.0× | 40 | 1.4k | ||
| Kouji Kajinami Japan | 27 | 1.4k 1.5× | 424 1.1× | 141 0.5× | 498 1.9× | 462 2.0× | 82 | 2.3k | ||
| Michael Stepanavage United States | 11 | 905 1.0× | 540 1.4× | 167 0.6× | 242 0.9× | 254 1.1× | 16 | 1.3k | ||
| Min‐Ji Charng Taiwan | 16 | 883 0.9× | 522 1.3× | 170 0.6× | 582 2.2× | 334 1.4× | 40 | 2.3k | ||
| Anja Vogt Germany | 19 | 1.1k 1.2× | 353 0.9× | 296 1.0× | 397 1.5× | 234 1.0× | 66 | 1.5k | ||
| Mary Jane Geiger United States | 20 | 748 0.8× | 542 1.4× | 246 0.8× | 552 2.1× | 237 1.0× | 31 | 2.5k |
Countries citing papers authored by David Neff
Since
Specialization
Citations
This map shows the geographic impact of David Neff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Neff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Neff more than expected).
Fields of papers citing papers by David Neff
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by David Neff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Neff. The network helps show where David Neff may publish in the future.
Co-authorship network of co-authors of David Neff
This figure shows the co-authorship network connecting the top 25 collaborators of David Neff. A scholar is included among the top collaborators of David Neff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Neff. David Neff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Virani, Salim S., Karen Aspry, Dave L. Dixon, et al.. (2023). The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. Journal of clinical lipidology. 17(2). 208–218.
2.
Ference, Brian A., et al.. (2017). GENETIC TARGET VALIDATION FOR ATP-CITRATE LYASE INHIBITION. Journal of the American College of Cardiology. 69(11). 1655–1655.
3.
Ference, Brian A., Jennifer G. Robinson, Robert D. Brook, et al.. (2016). Variation inPCSK9andHMGCRand Risk of Cardiovascular Disease and Diabetes. New England Journal of Medicine. 375(22). 2144–2153.
4.
Davidson, Michael H., Joanne E. Tomassini, Erin Jensen, et al.. (2015). Time-related trends in variability of cIMT changes in statin trials. Data in Brief. 6. 530–541.
5.
Davidson, Michael H., Joanne E. Tomassini, Erin Jensen, et al.. (2015). Changing characteristics of statin-related cIMT trials from 1988 to 2006. Atherosclerosis. 246. 121–129.
6.
Ashton, Veronica, Qiaoyi Zhang, Ning Jackie Zhang, et al.. (2014). LDL-C Levels in US Patients at High Cardiovascular Risk Receiving Rosuvastatin Monotherapy. Clinical Therapeutics. 36(5). 792–799.
7.
Wong, Nathan D., et al.. (2013). Residual Dyslipidemia Among United States Adults Treated With Lipid Modifying Therapy (Data from National Health and Nutrition Examination Survey 2009-2010). The American Journal of Cardiology. 112(3). 373–379.
8.
Foster, Meredith C., Andreea M. Rawlings, Elizabeth Marrett, et al.. (2013). Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United States. American Heart Journal. 166(1). 150–156.e1.
9.
Simpson, Ross J., Kaan Tunceli, Dena Rosen Ramey, et al.. (2013). Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting. Journal of clinical lipidology. 7(5). 399–407.
10.
Tóth, Peter P., JoAnne M. Foody, Joanne E. Tomassini, et al.. (2013). Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. Journal of clinical lipidology. 8(1). 107–116.
11.
Foster, Meredith C., Andreea M. Rawlings, Elizabeth Marrett, et al.. (2013). Potential Effects of Reclassifying CKD as a Coronary Heart Disease Risk Equivalent in the US Population. American Journal of Kidney Diseases. 63(5). 753–760.
12.
Lê, Anh, Ran Jin, Andrew M. Tershakovec, et al.. (2012). CHANGES IN LIPOPROTEIN PARTICLE NUMBER WITH EZETIMIBE/SIMVASTATIN COADMINISTERED WITH EXTENDED-RELEASE NIACIN IN PATIENTS WITH TYPE II HYPERLIPIDEMIA. Journal of the American College of Cardiology. 59(13). E1691–E1691.
13.
Keane, William F., Joanne E. Tomassini, & David Neff. (2012). Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis. Journal of Atherosclerosis and Thrombosis. 20(2). 123–133.
14.
Keane, William F., Joanne E. Tomassini, & David Neff. (2011). Lipid Abnormalities in Patients with Chronic Kidney Disease. Contributions to nephrology. 171. 135–142.
15.
Tóth, Peter P., Christie M. Ballantyne, Michael H. Davidson, et al.. (2011). Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. Journal of clinical lipidology. 6(2). 180–191.
16.
Davis, Harry R., Robert S. Lowe, & David Neff. (2011). Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis. 215(2). 266–278.
17.
Foody, JoAnne M., Shiva Sajjan, Henry Hu, et al.. (2010). LOSS OF EARLY GAINS IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOAL ATTAINMENT AMONG HIGH RISK PATIENTS. Journal of the American College of Cardiology. 55(10). A136.E1274–A136.E1274.
18.
Tunceli, Kaan, Shiva G. Sajjan, Dena Rosen Ramey, et al.. (2010). Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients. Journal of clinical lipidology. 4(6). 491–500.
19.
Foody, JoAnne M., Shiva G. Sajjan, Xiaohan Hu, et al.. (2010). Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients. Journal of clinical lipidology. 4(2). 126–132.
20.
Bays, Harold, David Neff, Joanne E. Tomassini, & Andrew M. Tershakovec. (2008). Ezetimibe: cholesterol lowering and beyond. Expert Review of Cardiovascular Therapy. 6(4). 447–470.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jong-Soon Park Breakdown of academic impact, for papers by Mary P. McGowan Breakdown of academic impact, for papers by Antonio J. Vallejo‐Vaz Breakdown of academic impact, for papers by Jonathan L. Isaacsohn Breakdown of academic impact, for papers by Emil M. deGoma Breakdown of academic impact, for papers by Kouji Kajinami Breakdown of academic impact, for papers by Michael Stepanavage Breakdown of academic impact, for papers by Min‐Ji Charng Breakdown of academic impact, for papers by Anja Vogt Breakdown of academic impact, for papers by Mary Jane Geiger